

- 7 hours ago
- 5 min
Alleviant Medical raises $75 million for clinical trials of novel technology to treat heart failure


- May 26
- 4 min
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharma to develop therapy for Parkinsons


- May 19
- 3 min
Acurx Pharmaceuticals prices $4 million placement to advance its new class of antibiotics


- May 12
- 6 min
Regentis Biomaterials to become listed on Nasdaq through a SPAC transaction


- May 11
- 3 min
Lexaria Bioscience prices $2 million public offering - proceeds to advance drug delivery technology

- May 10
- 4 min
Pressure BioScience’s Pressure-Based Tech Is Ready To Spur Innovation And Growth In Life Sciences


- May 6
- 6 min
MultiOmic Health Closes $6.2 Million for precision medicines for metabolic syndrome conditions


- May 5
- 3 min
Galmed Pharmaceuticals and OnKai partner for clinical studies in underserved communities

- May 3
- 4 min
Plus Therapeutics and Piramal Pharma Solutions expand collaboration for clinical trials


- Apr 25
- 2 min
ANI Pharmaceuticals obtains FDA Approval and launches its Nitrofurantoin Oral Suspension USP


- Apr 18
- 4 min
Aer Therapeutics raises $36 Million to advance development of a mucolytic for lung diseases

- Apr 14
- 4 min
Novo Holdings participates in $105 million funding in Alentis Therapeutics

- Apr 3
- 3 min
Orion is building a pharmaceutical research ecosystem using data and artificial intelligence


- Mar 30
- 3 min
Viking Therapeutics prices $250 Million public common stock offering

- Mar 28
- 3 min
EpiBiologics raises $50 million for next-generation antibody-based protein degradation platform


- Mar 4
- 3 min
Prana Thoracic raises $3 million to advance its lung tissue excision tool for lung cancer


- Mar 2
- 6 min
Mitsubishi Tanabe Pharma America announces preliminary results from Phase 3 ALS Trial

- Feb 24
- 5 min
Transcend Therapeutics, a mental health-focused biotechnology company, closes on $40 million


- Feb 22
- 3 min
Rare and orphan disease focused Quoin Pharmaceuticals (Nasdaq: QNRX) prices $7 million placement

- Feb 17
- 3 min
LifeArc Ventures participates in a $16 million financing for Maxion Therapeutics for antibody drugs